Exelixis
EXEL
#1680
Rank
HK$79.15 B
Marketcap
HK$277.19
Share price
2.24%
Change (1 day)
63.95%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : HK$5.33 Billion

According to Exelixis's latest financial reports the company's total liabilities are HK$5.33 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31HK$5.29 B16.31%
2022-12-31HK$4.55 B44.03%
2021-12-31HK$3.16 B58%
2020-12-31HK$2.00 B28.71%
2019-12-31HK$1.55 B47.3%
2018-12-31HK$1.05 B-63.51%
2017-12-31HK$2.89 B-26.32%
2016-12-31HK$3.92 B7.09%
2015-12-31HK$3.66 B7.92%
2014-12-31HK$3.39 B0.27%
2013-12-31HK$3.38 B2.96%
2012-12-31HK$3.29 B40.04%
2011-12-31HK$2.35 B-48.73%
2010-12-31HK$4.58 B16.59%
2009-12-31HK$3.93 B11.13%
2008-12-31HK$3.53 B38.94%
2007-12-31HK$2.54 B7.42%
2006-12-31HK$2.37 B11.02%
2005-12-31HK$2.13 B14.17%
2004-12-31HK$1.87 B22.91%
2003-12-31HK$1.52 B19.56%
2002-12-31HK$1.27 B49.2%
2001-12-31HK$0.85 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
HK$464.58 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$473.60 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
HK$568.01 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$595.24 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$648.84 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$841.67 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$987.92 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.39 B-92.54%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.56 B-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA